Treace Medical Concepts, Inc. (TMCI) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 23, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TMCI SEC filings page.
Treace Medical Concepts, Inc. (TMCI) reported $205.3M in revenue over the twelve months to Jun 30, 2026, down 4.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue has nearly stopped growing while persistent losses and negative cash flow leave the business reliant on balance-sheet resources.
The key shift is cash conversion, not profitability: operating cash flow improved from-$37.2M in FY2024 to-$16.0M in FY2025. Yet reinvestment remains cash-consuming: free cash flow was-$29.5M after$13.5M of capital spending, so the operating improvement has not funded reinvestment.
Margin compression is gradual: gross margin moved from
Reported liquidity equaled 36.3 months of the latest annual operating outflow, while the current ratio remained 4.3x, so short-term obligations were not the immediate constraint shown by these measures. Debt-to-equity rose from 0.5x to 0.6x as equity declined, indicating a more leveraged financing structure even before liquidity tightened.
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Treace Medical Concepts, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Treace Medical Concepts, Inc. has an operating margin of -25.5%, meaning the company loses $25 on every $100 of revenue. This results in a profitability score of 32/100. This is up from -26.6% the prior year.
Treace Medical Concepts, Inc.'s revenue grew a modest 1.6% year-over-year to $212.7M. This slow but positive growth earns a score of 55/100.
Treace Medical Concepts, Inc. has a moderate D/E ratio of 0.64. This balance of debt and equity financing earns a leverage score of 55/100.
With a current ratio of 4.31, Treace Medical Concepts, Inc. holds $4.31 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 89/100.
Treace Medical Concepts, Inc.'s operations used $16.0M of cash, and capex of $13.5M added to the outflow, for a free cash flow shortfall of $29.5M. This results in a cash flow score of 9/100.
Treace Medical Concepts, Inc. posts a -67.6% return on equity (ROE), meaning it loses $68 for every $100 of shareholders' equity. This results in a returns score of 28/100. This is down from -49.4% the prior year.
Treace Medical Concepts, Inc. scores 0.60, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $249.0M against total assets of $190.6M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Treace Medical Concepts, Inc. passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 operating efficiency signals passes.
Treace Medical Concepts, Inc. reported a net loss of $59.0M while operations used $16.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Treace Medical Concepts, Inc. reported an operating loss of $54.2M against $5.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Treace Medical Concepts, Inc. generated $45.4M in revenue in Q2 2026. This represents a decrease of 4.2% from the same quarter a year earlier. Against the prior quarter it is down 3.9%.
Treace Medical Concepts, Inc.'s EBITDA was -$13.5M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Treace Medical Concepts, Inc. reported a net loss of $15.9M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Treace Medical Concepts, Inc. earned -$0.24 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Treace Medical Concepts, Inc. recorded an outflow of $6.9M in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 265.1%.
Treace Medical Concepts, Inc. held $12.6M in cash against $56.0M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Treace Medical Concepts, Inc.'s gross margin was 78.5% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 1.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.8 percentage points.
Treace Medical Concepts, Inc.'s operating margin was -33.0% in Q2 2026, reflecting core business profitability. This is up 2.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.4 percentage points.
Treace Medical Concepts, Inc.'s net profit margin was -35.0% in Q2 2026, showing the share of revenue converted to profit. This is up 1.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.1 percentage points.
Treace Medical Concepts, Inc.'s quarterly ROE was -23.4% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 5.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.2 percentage points.
Capital Allocation
Treace Medical Concepts, Inc. invested $4.4M in research and development in Q2 2026. This represents a decrease of 20.4% from the same quarter a year earlier. Against the prior quarter it is down 5.3%.
Treace Medical Concepts, Inc. invested $2.2M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 53.8% from the same quarter a year earlier. Against the prior quarter it is down 28.1%.
Not reported for Q2 2026.
TMCI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $45.4M-4.2% | $47.2M-10.2% | $62.5M-9.0% | $50.2M+11.4% | $47.4M+6.6% | $52.6M+2.9% | $68.7M+10.4% | $45.1M+10.6% |
| Cost of Revenue | $9.8M+1.4% | $9.8M-8.3% | $12.1M-8.4% | $10.5M+17.4% | $9.6M+9.7% | $10.7M+5.4% | $13.2M+15.4% | $9.0M+12.0% |
| Gross Profit | $35.6M-5.7% | $37.4M-10.7% | $50.4M-9.1% | $39.7M+9.9% | $37.8M+5.8% | $41.9M+2.2% | $55.5M+9.3% | $36.1M+10.3% |
| R&D Expenses | $4.4M-20.4% | $4.6M-16.9% | $4.5M-12.8% | $4.7M-5.7% | $5.5M+6.6% | $5.6M+5.8% | $5.2M+25.5% | $5.0M+14.1% |
| SG&A Expenses | $46.2M-6.2% | $50.0M-3.8% | $51.8M+2.6% | $50.7M+9.5% | $49.2M-5.1% | $51.9M-5.1% | $50.5M-5.4% | $46.3M+0.2% |
| Operating Income | -$15.0Mn/m | -$17.2Mn/m | -$5.9Mn/m | -$15.7Mn/m | -$17.0Mn/m | -$15.6Mn/m | -$204Kn/m | -$15.1Mn/m |
| EBITDA | -$13.5Mn/m | -$16.3Mn/m | -$2.8M-239.6% | -$12.9Mn/m | -$14.7Mn/m | -$13.1Mn/m | $2.0Mn/m | -$13.0Mn/m |
| Interest Expense | $1.6M+18.2% | $1.6M+19.8% | $1.4M+2.7% | $1.3M+1.9% | $1.3M+0.7% | $1.3M-0.5% | $1.3M+0.8% | $1.3M+1.3% |
| Net Income | -$15.9Mn/m | -$18.0Mn/m | -$9.4Mn/m | -$16.3Mn/m | -$17.4Mn/m | -$15.9Mn/m | -$501Kn/m | -$15.4Mn/m |
| EPS (Basic) | -$0.24n/m | -$0.28n/m | -$0.14n/m | -$0.26n/m | -$0.28n/m | -$0.25n/m | -$0.01n/m | -$0.25n/m |
| EPS (Diluted) | -$0.24n/m | -$0.28n/m | -$0.14n/m | -$0.26n/m | -$0.28n/m | -$0.25n/m | -$0.01n/m | -$0.25n/m |
| Diluted Shares (Avg) | 65M+3.2% | 65M+3.1% | N/A | 64M+2.1% | 63M+1.5% | 63M+1.4% | N/A | 62M+1.1% |
Not reported in any period shown, so not listed: Income Tax.
TMCI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $181.1M-12.3% | $184.1M-10.6% | $190.6M-12.2% | $196.6M-7.7% | $206.4M-8.7% | $205.8M-15.2% | $217.1M-13.8% | $212.9M-11.4% |
| Current Assets | $120.5M-18.4% | $123.5M-17.4% | $132.1M-18.2% | $138.0M-12.4% | $147.6M-14.0% | $149.4M-20.3% | $161.4M-18.6% | $157.6M-15.8% |
| Cash & Equivalents | $12.6M+56.6% | $9.5M-28.6% | $10.7M-5.7% | $7.7M-36.5% | $8.1M-55.7% | $13.4M+43.3% | $11.3M-12.6% | $12.1M+66.4% |
| Short-Term Investments | $33.0M-46.1% | $42.3M-32.5% | $37.7M-41.5% | $49.7M-29.6% | $61.2M-20.3% | $62.7M-37.7% | $64.3M-41.6% | $70.7M-38.5% |
| Inventory | $39.5M-6.7% | $36.4M-4.1% | $36.0M-8.2% | $41.4M-5.0% | $42.4M+2.7% | $37.9M+5.8% | $39.3M+34.2% | $43.6M+48.8% |
| Accounts Receivable | $28.7M-5.3% | $30.4M-2.4% | $42.2M+3.3% | $33.0M+36.3% | $30.3M+18.7% | $31.1M+3.4% | $40.8M+7.1% | $24.2M-3.3% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $12.8M0.0% | $12.8M0.0% | $12.8M0.0% | $12.8M0.0% | $12.8M0.0% | $12.8M0.0% | $12.8M0.0% | $12.8M0.0% |
| Total Liabilities | $113.3M+4.1% | $106.9M+6.4% | $103.2M-0.9% | $107.4M-0.6% | $108.8M-4.5% | $100.5M-13.6% | $104.2M-8.6% | $108.0M+5.4% |
| Current Liabilities | $41.5M-1.0% | $34.5M+4.0% | $30.6M-12.3% | $40.9M+6.9% | $41.9M-5.7% | $33.2M-29.5% | $34.9M-22.4% | $38.3M+15.4% |
| Non-Current Liabilities | $71.8M+7.3% | $72.4M+7.6% | $72.6M+4.8% | $66.5M-4.7% | $66.9M-3.7% | $67.3M-2.8% | $69.3M+0.5% | $69.8M+0.6% |
| Long-Term Debt | $56.0M+4.8% | $55.8M+4.6% | $55.6M+4.3% | $53.5M+0.6% | $53.5M+0.6% | $53.4M+0.6% | $53.3M+0.6% | $53.2M+0.6% |
| Total Equity | $67.7M-30.6% | $77.2M-26.7% | $87.3M-22.6% | $89.2M-15.0% | $97.6M-13.0% | $105.3M-16.7% | $112.9M-18.2% | $104.9M-23.9% |
| Retained Earnings | -$282.8Mn/m | -$267.0Mn/m | -$249.0Mn/m | -$239.6Mn/m | -$223.3Mn/m | -$205.9Mn/m | -$190.0Mn/m | -$189.5Mn/m |
TMCI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.7Mn/m | $7.2M+72.5% | -$8.0Mn/m | -$9.1Mn/m | -$3.0Mn/m | $4.2Mn/m | -$4.2M-890.8% | -$11.8Mn/m |
| Depreciation & Amortization | $1.5M-34.8% | $899K-63.5% | $2.8M+25.5% | $2.8M+28.8% | $2.3M+8.7% | $2.5M+28.9% | $2.2M+26.5% | $2.2M+37.9% |
| Stock-Based Compensation | $6.5M-32.5% | $8.0M-7.6% | N/A | $8.0M+1.2% | $9.6M+42.1% | $8.7M+17.3% | N/A | $7.9M+52.2% |
| Capital Expenditures | $2.2M-53.8% | $3.1M-13.6% | $2.4M-22.0% | $2.8M-1.9% | $4.8M+175.7% | $3.5M-9.8% | $3.1M+36.7% | $2.9M-18.2% |
| Free Cash Flow | -$6.9Mn/m | $4.2M+537.9% | -$10.4Mn/m | -$11.9Mn/m | -$7.8Mn/m | $655Kn/m | -$7.3Mn/m | -$14.7Mn/m |
| Investing Cash Flow | $7.1Mn/m | -$7.8Mn/m | $9.7M+182.5% | $8.7M+51.6% | -$3.3M-114.5% | -$1.9M-150.4% | $3.4M-31.7% | $5.8M+25.4% |
| Financing Cash Flow | $696K-29.5% | -$588Kn/m | $1.4M+5215.4% | -$10K-225.0% | $987K+217.4% | -$282Kn/m | $26K-84.2% | $8K-95.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TMCI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.5%-1.2pp | 79.3%-0.4pp | 80.6%-0.1pp | 79.1%-1.1pp | 79.7%-0.6pp | 79.7%-0.5pp | 80.7%-0.8pp | 80.1%-0.2pp |
| Operating Margin | -33.0%+2.9pp | -36.4%-6.7pp | -9.5%-9.2pp | -31.2%+2.4pp | -35.8%+12.3pp | -29.6%+7.5pp | -0.3%+10.6pp | -33.6%+10.1pp |
| Net Margin | -35.0%+1.7pp | -38.0%-7.8pp | -15.0%-14.3pp | -32.4%+1.6pp | -36.7%+11.0pp | -30.3%+6.3pp | -0.7%+9.4pp | -34.1%+8.9pp |
| Return on Equity | -23.4%-5.6pp | -23.3%-8.2pp | -10.8%-10.3pp | -18.3%-3.6pp | -17.8%+1.1pp | -15.1%-0.3pp | -0.4%+4.1pp | -14.6%-1.9pp |
| Return on Assets | -8.8%-0.3pp | -9.8%-2.0pp | -4.9%-4.7pp | -8.3%-1.1pp | -8.4%+0.9pp | -7.7%0.0pp | -0.2%+2.3pp | -7.2%+0.1pp |
| Current Ratio | 2.90-0.6x | 3.58-0.9x | 4.31-0.3x | 3.37-0.7x | 3.52-0.3x | 4.50+0.5x | 4.62+0.2x | 4.12-1.5x |
| Debt-to-Equity | 0.83+0.3x | 0.72+0.2x | 0.64+0.2x | 0.60+0.1x | 0.55+0.1x | 0.51+0.1x | 0.47+0.1x | 0.51+0.1x |
| Liabilities-to-Equity | 1.67+0.6x | 1.39+0.4x | 1.18+0.3x | 1.20+0.2x | 1.11+0.1x | 0.950.0x | 0.92+0.1x | 1.03+0.3x |
| Asset Turnover | 0.250.0x | 0.260.0x | 0.330.0x | 0.260.0x | 0.230.0x | 0.260.0x | 0.32+0.1x | 0.210.0x |
| FCF Margin | -15.2%+1.3pp | 8.8%+7.6pp | -16.7%-6.1pp | -23.7%+8.9pp | -16.5%+18.6pp | 1.3%+23.1pp | -10.6%-7.8pp | -32.6%-0.7pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Treace Medical Concepts, Inc. TMCI | FY2025 | $212.7M | -$59.0M | -27.7% | $277.7M | 45/100 |
| OrthoPediatrics Corp. KIDS | FY2025 | $236.3M | -$39.6M | -16.8% | $639.7M | 56/100 |
| Bioventus Inc. BVS | FY2025 | $568.1M | $22.7M | 4.0% | $1.0B | 42/100 |
| Cytek Biosciences, Inc. CTKB | FY2025 | $201.5M | -$66.5M | -33.0% | $726.6M | 45/100 |
| CeriBell, Inc. CBLL | FY2025 | $89.1M | -$53.4M | -60.0% | $1.0B | 52/100 |
Where Treace Medical Concepts, Inc. Ranks
Frequently Asked Questions
What is Treace Medical Concepts, Inc.'s annual revenue?
Treace Medical Concepts, Inc. (TMCI) reported $212.7M in total revenue for fiscal year 2025. This represents a 1.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Treace Medical Concepts, Inc.'s revenue growing?
Treace Medical Concepts, Inc. (TMCI) revenue grew by 1.6% year-over-year, from $209.4M to $212.7M in fiscal year 2025.
Is Treace Medical Concepts, Inc. profitable?
No, Treace Medical Concepts, Inc. (TMCI) reported a net loss of $59.5M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net loss of $59.0M, with a net profit margin of -27.7%.
What is Treace Medical Concepts, Inc.'s EBITDA?
Treace Medical Concepts, Inc. (TMCI) had EBITDA of -$43.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Treace Medical Concepts, Inc. have?
As of fiscal year 2025, Treace Medical Concepts, Inc. (TMCI) had $10.7M in cash and equivalents against $55.6M in long-term debt.
What is Treace Medical Concepts, Inc.'s gross margin?
Treace Medical Concepts, Inc. (TMCI) had a gross margin of 79.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Treace Medical Concepts, Inc.'s operating margin?
Treace Medical Concepts, Inc. (TMCI) had an operating margin of -25.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Treace Medical Concepts, Inc.'s net profit margin?
Treace Medical Concepts, Inc. (TMCI) had a net profit margin of -27.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Treace Medical Concepts, Inc.'s return on equity (ROE)?
Treace Medical Concepts, Inc. (TMCI) has a return on equity of -67.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Treace Medical Concepts, Inc.'s free cash flow?
Treace Medical Concepts, Inc. (TMCI) recorded an outflow of $29.5M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Treace Medical Concepts, Inc.'s operating cash flow?
Treace Medical Concepts, Inc. (TMCI) recorded an outflow of $16.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Treace Medical Concepts, Inc.'s total assets?
Treace Medical Concepts, Inc. (TMCI) had $190.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Treace Medical Concepts, Inc.'s capital expenditures?
Treace Medical Concepts, Inc. (TMCI) invested $13.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Treace Medical Concepts, Inc. spend on research and development?
Treace Medical Concepts, Inc. (TMCI) invested $20.3M in research and development during fiscal year 2025.
What is Treace Medical Concepts, Inc.'s current ratio?
Treace Medical Concepts, Inc. (TMCI) had a current ratio of 4.31 as of fiscal year 2025, which is generally considered healthy.
What is Treace Medical Concepts, Inc.'s debt-to-equity ratio?
Treace Medical Concepts, Inc. (TMCI) had a debt-to-equity ratio of 0.64 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is Treace Medical Concepts, Inc.'s liabilities-to-equity ratio?
Treace Medical Concepts, Inc. (TMCI) had a liabilities-to-equity ratio of 1.18 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is Treace Medical Concepts, Inc.'s return on assets (ROA)?
Treace Medical Concepts, Inc. (TMCI) had a return on assets of -31.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Treace Medical Concepts, Inc.'s P/E ratio?
Treace Medical Concepts, Inc. (TMCI) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $277.7M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Treace Medical Concepts, Inc.'s price-to-sales ratio?
Treace Medical Concepts, Inc. (TMCI) trades at 1.4x sales, its market capitalization divided by $205.3M revenue, trailing 12 months to June 30, 2026. The market capitalization is $277.7M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Treace Medical Concepts, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Treace Medical Concepts, Inc. (TMCI) held $48.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $16.0M over that year. Dividing the one by the other, the reported balance equals about 36 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Treace Medical Concepts, Inc.'s Altman Z-Score?
Treace Medical Concepts, Inc. (TMCI) has an Altman Z-Score of 0.60, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Treace Medical Concepts, Inc.'s Piotroski F-Score?
Treace Medical Concepts, Inc. (TMCI) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Treace Medical Concepts, Inc.'s earnings high quality?
Treace Medical Concepts, Inc. (TMCI) reported a net loss of $59.0M while operations used $16.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Treace Medical Concepts, Inc. cover its interest payments?
Treace Medical Concepts, Inc. (TMCI) reported an operating loss of $54.2M against $5.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Treace Medical Concepts, Inc.?
Treace Medical Concepts, Inc. (TMCI) scores 45 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.